Canadian biopharma company Algernon Pharmaceuticals Inc. AGNPF’s subsidiary Algernon NeuroScience (AGN Neuro) completed dosing the second cohort of its Phase 1 study on the company’s proprietary IV ...
Biomind Labs Inc. BMNDF, a life sciences company developing medicinal next-generation psychedelics, completed the dose administration of 30 healthy subjects within its Phase 2 clinical trial of ...
Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to provide an update on subsidiary Algernon NeuroScience successfully completing the highest planned single dose of ...
VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage ...
The HyperCard inventor was a huge proponent of taking lower doses of 5-MeO-DMT, which is widely considered the strongest ...
From the dark annals of Erowid forums to Joe Rogan’s podcast studio, there’s perhaps no psychoactive drug more enigmatic — and misunderstood — than N,N-Dimethyltryptamine, better known as DMT. The ...
-- Expected to accelerate clinical development pathway of CYB004 for the potential treatment of anxiety disorders by nine months -- About the CYB004-E Study The CYB004-E study is an adaptive, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback